PRESSEFACH
WEITERE ADHOC-MELDUNGEN
Weng Fine Art beschließt Veräußerung von 50.000 eigenen Aktien
Veröffentlichung einer Kapitalmarktinformation
Alternative Gegenleistung zum freiwilligen Erwerbsangebot für Biofrontera-Aktien
Korrektur zur Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vertriebspartnerschaft mit SoftwareCentral
Ferax Capital AG veröffentlicht Halbjahreszahlen 2018
SHF Communication Technologies AG hebt Umsatz- und Ergebnisprognose für das Geschäftsjahr 2018 an
 
MELDUNG VOM 11.04.2018 07:30
Meldung drucken Artikel weiterleiten
pta20180411008
Business news for the stock market
Pressefach Pressefach

Medigene AG: Medigene appoints Dr. Kai Pinkernell to the Executive Management Board as CMO/CDO

Planegg (pta008/11.04.2018/07:30) - Die Medigene AG (MDG1, Frankfurt, Prime Standard, TecDAX) announced today the appointment of Dr. Kai Pinkernell to the Executive Management Board of the Company as Chief Medical Officer (CMO) and Chief Development Officer (CDO). Dr. Pinkernell has been with Medigene as Senior Vice President and Chief Medical Officer (CMO) since February 2016.

Prof. Dolores Schendel, CEO/CSO of Medigene AG, said, "The appointment of Kai and the expansion of the Executive Management Board is in line with Medigene's advancement as a clinical stage immuno-oncologic company. Following the successful start of the clinical Phase I/II trial with our TCR immune cell therapy MDG1011 in March, Medigene is one of the few companies worldwide with a TCR-based immunotherapy in clinical development. In addition, our Phase II DC vaccine trial is ongoing as scheduled. Kai has contributed significantly to this progress and will optimally support the further development of our immunotherapies at the Executive Board level. I look forward to our intensive collaboration."

Prof. Horst Domdey, Chairman of the Supervisory Board of Medigene, commented, "The appointment of Kai Pinkernell to the Management Board comes at the right time and reflects the Company's growing clinical focus. With this step, the Executive Management Board at Medigene will be optimally placed to address current and future tasks. We are very happy that Dr. Pinkernell excellently fulfills the qualifications needed for this important role in the Board of Management driving clinical development and product development. He has extensive, long-standing and highly successful leadership experience in both of these areas and I wish him every success in his new roles."

Dr. Kai Pinkernell, new member of the Executive Management Board and CMO/CDO at Medigene, added, "I see great potential in Medigene's Research & Development projects. With our recently started TCR clinical trial, a very exciting and important phase of our corporate development has commenced. I am grateful that this responsible position is now assigned to me and I am very much looking forward to progressing the clinical and product development of Medigene in order to offer new innovative therapy options to seriously ill patients in the future."

Dr. Kai Pinkernell is responsible for the clinical development, regulatory affairs and manufacturing of Medigene's products. He has 17 years of expertise in global clinical development of cell therapies including preclinical activities, the automation and GMP production as well as in commercialization and business development activities. Before joining Medigene, he held various management positions at Miltenyi Biotech GmbH, Bergisch Gladbach, Germany, most recently as Global Head of Clinical Business and Head of Clinical Development. Before that, Dr. Pinkernell served as Senior Director of Regenerative Cell Technology for Cytori Therapeutics Inc. of San Diego, USA. He studied medicine and obtained his doctorate at the Westfälische Wilhelms-University Münster. In addition, Dr. Pinkernell holds a Master of Business Administration from the Marshall School of Business, University of Southern California, Los Angeles, USA.

***
Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.
For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(Ende)

Aussender: Medigene AG
Lochhamer Straße 11
82152 Planegg
Deutschland
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 33 3301
E-Mail:
Website: www.medigene.de
ISIN(s): DE000A1X3W00 (share)
Börsen: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
Medigene AG
AKTUELLE BUSINESS NEWS
20.07.2018 17:30
Filterhersteller Dexwet drängt an die NASDAQ
Dexwet International AG
20.07.2018 13:47
Deutsche Start-ups verzichten auf Geld vom Staat
pressetext.redaktion
20.07.2018 10:00
D.A.S.: Zehntes Mal in Folge mit A-Rating
D.A.S. Rechtsschutz AG
20.07.2018 06:10
"Atmosphärische Führung" steigert Produktivität
pressetext.redaktion
19.07.2018 11:30
Griechenlands Privatwirtschaft hat kaum Potenzial
pressetext.redaktion
Weitere News anzeigen